Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer

被引：3
|
作者：
Hudis, CA [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 01期
关键词：
breast cancer; chemotherapy; HER2; survival; trastuzumab;
D O I：
10.1038/ncponc0401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 50 条
  • [31] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
  • [32] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
    Al-Naqqash, Manwar
    Jasim Al-Serarati, Waleed
    Farooq Kareem, Tara
    BREAST JOURNAL, 2021, 27 (03) : 297 - 299
  • [33] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [34] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
    Milani, Andrea
    Montemurro, Filippo
    Gioeni, Luisa
    Aglietta, Massimo
    Valabrega, Giorgio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
  • [35] Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
    Naoki Kanomata
    Junichi Kurebayashi
    Takuya Moriya
    Medical Molecular Morphology, 2019, 52 : 106 - 113
  • [36] Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era
    Palmieri, Carlo
    Shah, Deep
    Krell, Jonathan
    Gojis, Ondrej
    Hogben, Katy
    Riddle, Pippa
    Ahmad, Riz
    Tat, Tri
    Fox, Kevin
    Porter, Andrew
    Mahmoud, Sarah
    Kirschke, Stephanie
    Shousha, Sami
    Gudi, Mihir
    Coombes, R. Charles
    Leonard, Robert
    Cleator, Susan
    CLINICAL BREAST CANCER, 2011, 11 (02) : 93 - 102
  • [37] Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
    Eiermann, W
    ANNALS OF ONCOLOGY, 2001, 12 : 57 - 62
  • [38] The Adjuvant Treatment of HER2-Positive Breast Cancer
    Danijela Jelovac
    Antonio C. Wolff
    Current Treatment Options in Oncology, 2012, 13 : 230 - 239
  • [39] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [40] How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
    Morganti, S.
    Bianchini, G.
    Giordano, A.
    Giuliano, M.
    Curigliano, G.
    Criscitiello, C.
    ESMO OPEN, 2022, 7 (02)
12345